b r i e f c o m m u n i c a t i o n s
Genome-wide association studies (GWAS) have identified SNP markers associated with risk for prostate [1] [2] [3] [4] [5] , breast 6 , colon [7] [8] [9] and bladder 10 cancers for at least five distinct loci within a ~600-kb region of 8q24.21. Though this region contains no known protein-coding genes, an adjacent gene, the c-myc oncogene (MYC), is an attractive candidate for association because of its established role in carcinogenesis. There is no evidence that common genetic variants in MYC or its proximal promoters are in linkage disequilibrium (LD) with markers identified by GWAS, although recent studies have focused on the role of genetic variants on chromosome 8q24 and MYC expression and function 11 .
Three distinct regions within 8q24.21 have been associated with prostate cancer risk ( regions 1, 2 and 3) 12 . Region 3 (chr. 8: 128473069-128537116) is also associated with risk for colorectal and ovarian cancers 7, 13 , colorectal adenoma 14 , and kidney, larynx and thyroid cancers 15 . Centromeric to regions 1 and 3, rs13281615 (chr. 8: 128424800) was identified in a breast cancer GWAS 6 . Another locus telomeric to regions 1 and 3 has been associated with susceptibility to bladder cancer (rs9642880) 10 . The markers lie within distinct blocks of LD; from centromere to telomere, these blocks are region 2, the breast cancer region, region 3, region 1, and the bladder cancer region.
In stages 1-3 of the National Cancer Institute's (NCI)'s CGEMS initiative, in order to determine whether there are additional markers at 8q24.21 associated with prostate cancer risk, we genotyped 137 SNPs flanking regions 1 and 3 in 10,286 individuals with prostate cancer (cases) and 9,135 controls of European ancestry. SNPs were selected because they either tagged regions identified in previous cancer GWAS 3, 4, 6 or were previously genotyped in the second stage of CGEMS 5 . Specifically, we genotyped 82 SNPs across a segment (chr. 8: 128,154,828-128,472,696) centromeric to regions 1 and 3 that includes region 2 and the breast cancer region. Telomeric to regions 1 and 3, we genotyped 55 SNPs spanning a region identified in a bladder cancer GWAS (chr. 8: 128,617,860-128,816,653). Cases and controls were drawn from ten studies from Europe and the United States (Supplementary Methods). Single-SNP association tests were conducted using unconditional logistic regression (genotype tests with two degrees of freedom, d.f.), adjusted for study, study center (when applicable) and four continuous covariates to account for potential population stratification (see Supplementary Methods).
We identified a marker, the C allele of rs620861, to be strongly associated with prostate cancer risk (genotype score test, 2 d.f., P = 1.30 × 10 -10 , heterozygote OR = 1.17, homozygote OR = 1.33; Table 1 , Fig. 1 and Supplementary Table 1 ). Although this region has not been previously implicated in prostate cancer, rs620861 is centromeric to rs13281615, a marker associated with breast cancer susceptibility 6 . Modest LD was observed between rs620861 and rs13281615 6 (r 2 = 0.38). In our study, rs13281615 showed a less significant association (P = 0.010, Table 1 ) with prostate cancer, and after adjustment for rs620861, rs13281615 was unremarkable (P = 0.142), indicating that it does not confer risk independently of rs620861. An additional SNP (rs445114) within this region was also significantly associated with prostate cancer risk (P = 1.54 × 10 -9 ; Table 1 ), but this finding most likely points toward the same locus because of its strong correlation with rs620861 among controls (pairwise r 2 = 0.94).
The two markers for regions 1 and 3, rs4242382 and rs6983267 were most strongly associated with prostate cancer risk, similar to the findings from our previous report 5 . rs620861 was not correlated with either of these SNPs. Based on data from 9,135 control individuals (analyzed and reported by geographic region and also by study; see Supplementary  Table 2) , LD between rs620861 and rs4242382 (region 1) 5 and rs6983267 (region 3) 5 is negligible (r 2 = 7.8 × 10 -4 and 9.6 × 10 -3 , respectively). Similarly, rs620861 is not correlated with markers tested in region 2 (all pairwise r 2 ≤ 9 × 10 -3 ). rs620861 remained strongly associated (P = 1.13 × 10 -8 ) with prostate cancer risk after adjustment Identification of a new prostate cancer susceptibility locus on chromosome 8q24
We report a genome-wide association study in 10,286 cases and 9,135 controls of European ancestry in the Cancer Genetic Markers of Susceptibility (CGEMS) initiative. We identify a new association with prostate cancer risk on chromosome 8q24 (rs620861, Table 3) .
We genotyped 18 SNPs across region 2 and observed three markers significantly associated with prostate cancer risk (rs7841060 G, P = 1.48 × 10 -13 ; rs4871008 C, P = 6.16 × 10 -10 ; rs6470494 T, P = 4.49 × 10 -8 ; Table 1 and Supplementary Table 4) . We compared our results with those of a previously reported rare 14-SNP haplotype (known as HapC, minor allele frequency (MAF) = 2%) 3 that contains the A allele of a low-frequency (3.8%) SNP, rs16901979, showing a significant association with prostate cancer risk. Four SNPs (rs6470494, rs1016342, rs1378897 and rs1456305) of the 14-SNP HapC were tested in the present study 3 . Based on HapMap CEU data (build 26), an additional five markers were correlated at r 2 > 0.8 with HapC SNPs, including rs7841060 (r 2 = 1, HapC: rs1016343) and rs4871008 (r 2 = 0.96, HapC: rs1551510); thus, rs7841060 is a surrogate for a component of HapC 3 .
We explored the effect of rs7841060 after adjusting for rs16901979, a surrogate for HapC. Because rs16901979 was not included in the stage 3 assay, we genotyped rs16901979 using TaqMan in a subset of subjects from stages 1 and 2 (4,888 controls, 5,005 cases) and observed a significant association with prostate cancer (P = 6.27 × 10 -8 ) assuming a multiplicative risk model. In evaluating the same subset of cases and controls for association with rs7841060, we obtained a P value of 1.41 × 10 -6 under the same model. In a logistic regression of both SNPs assuming log-additive effects and no interaction, each SNP remained significant when adjusted for the other (rs7841060, P = 5.5 × 10 -4 ; rs16901979, P = 4.1 × 10 -5 ). Results of a test for nonmultiplicative interaction were not significant (P = 0.17). Although the risk alleles of the common SNP rs7841060 (MAF = 22.3%) and rare SNP rs16901979 (MAF = 3.8%) tend to co-segregate (D′ = 0.87, r 2 = 0.11), an additional copy of the G allele at rs7841060 appears to confer additional risk for prostate cancer. The identification here of the association of rs7841060 to prostate cancer ssceptibility suggests that the genomic architecture underlying this region could be complex and may also indicate the presence of additional lower risk variants.
No evidence of association with prostate cancer was observed for 57 SNPs telomeric of prostate cancer region 1 ( Supplementary  Fig. 1 and Supplementary Table 4) .
In our large dataset, we explored the possibility of a nonmultiplicative effect between six pairs of the four independent loci (including the previously unrecognized one reported herein) that have been associated with prostate cancer. We observed departures from a multiplicative odds ratios model between rs4242382 (region 1) 5 and rs620861 (P = 2.2 × 10 -3 based on a 1-d.f. test for non-multiplicative effect) (Supplementary Fig. 2 and Supplementary Table 5); this observation remained noteworthy after Bonferroni adjustment (P = 0.013). There was no clear pattern of association between rs4242382 and prostate cancer in the absence of the C risk allele for rs620861, but we did observe strong trends in risk by allele count of rs4242382 in the presence of either one or two copies of risk alleles for rs620861. Furthermore, the association trend between rs620861 and prostate cancer risk is stronger in the presence of the two at-risk alleles for rs4242382. There was no evidence for significant non-multiplicative effects for regions 2 and 3.
In follow-up of GWAS findings for 8q24, we identified a previously unidentified SNP marker (rs620861) in a locus previously associated with breast cancer risk that remains highly significant (P = 1.13 × 10 -8 ) after adjustment for other known 8q24 SNPs. Our data also provide evidence that multiple variants may independently contribute to the risk of prostate cancer in region 2; rs7841060, in conjunction with and perhaps also independently of rs16901979, contributes to prostate cancer risk. Our findings underscore the importance of exploring regions of association with dense genotyping in follow-up studies and expand the number of loci on 8q24 identified to be independently associated with prostate cancer risk. Further investigation is warranted to determine the molecular basis of each of the prostate susceptibility loci at 8q24 and the possible interaction between these loci. Region 4 is the new locus and region 2 is the locus previously known as the breast cancer locus. The effect of rs620861 is comparable in aggressive (Gleason 7+ or stage 2/3) and non-aggressive cases based on a combined joint analysis by polytomous logistic regression (supplementary table 1) . The genotype association test with 2 degrees of freedom adjusted for study, center (when applicable, for PLCO, CeRePP and EPIC; see supplementary methods) and four eigenvectors determined by significant principal component analysis per study (using 1,400 SNPs with r 2 < 0.004 in CGEMS control dataset of 9,135). For regions 1 and 3, rs4242382 and rs6983267 remained the most highly significant markers (P = 6.66 × 10 -21 and P = 5.76 × 10 -23 , respectively). Ctrls., controls; het., heterozygous; hom., homozygous.
